Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Seeks New R&D Tax Credit Scheme for Strategic Technologies in FY2026 Proposal
August 27, 2025
- Public-Private Council WG on Drug Discovery to Hold First Meeting Sept. 1
August 26, 2025
- Japan Approves 3 New Drugs, Expands Label for Enhertu, Silgard 9 and More
August 26, 2025
- No Inflation Measures for Drugs Mentioned in FY2026 Budget Request: MHLW Draft
August 25, 2025
- MHLW Panel Endorses Orphan Tag for 2 Regenerative Medicine Products
August 25, 2025
- Novartis’ Radioligand Therapy, More Meds Inch Closer to Japan Approval with Panel OK
August 25, 2025
- Vonoprazan Gets Panel Backing for Rx-to-OTC Switch
August 25, 2025
- PMDA’s “Early Considerations” Start to Pay Off with Faster Reviews
August 22, 2025
- Japan Mulls Preferential R&D Tax Credits for Strategic Technologies in FY2026 Reform Talks
August 22, 2025
- AMED to Put Practicality First in Project Selection: Ecosystem Coordinator
August 21, 2025
- MHLW FY2026 Budget Request to Focus on Clinical Trials, Early Regulatory Support
August 21, 2025
- Japan Moves to Bolster R&D and Stockpiling of Crisis-Response Medicines
August 20, 2025
- Astellas’ Izervay, Otsuka’s Nexletol among New Drugs Up for Japan Panel Review; Eylea Biosimilars Also on Agenda
August 19, 2025
- MHLW Official Vows Steady Implementation of Amended PMD Act
August 19, 2025
- Japan Weighs Legal Framework for Pharmaceutical Data Protection; JPMA Sees Opportunity for Reform
August 19, 2025
- MHLW’s New Pharma Chief Pledges Safer, More Accessible Drug Environment
August 19, 2025
- Nipro Secures AG for Forxiga, Sawai and Teva Takeda Go Without Hydrate
August 18, 2025
- Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
August 18, 2025
- MHLW Working Group Sets Policy for Revising List of “Stable Supply Medicines”
August 18, 2025
- Novartis’ Radioligand Therapy, Other New Meds Up for Japan Panel Review on Aug. 22
August 12, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…